Home Blog of Signal Transduction Metabolism Dehydrogenase

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

Dehydrogenase

Pycard deficiency inhibits microRNA maturation and prevents neointima formation by promoting chaperone-mediated autophagic degradation of AGO2/argonaute 2 in adipose tissue

50 views | Jan 06 2024

The study reveals that PYCARD regulates neointima formation by inhibiting chaperone-mediated autophagy-induced degradation of AGO2, impacting microRNA biogenesis independently of inflammasome activity, offering potential therapeutic strategies for vascular conditions. [Read the Full Post]

Molecular Profiling and Targeted Therapies in Gliomas

50 views | Dec 14 2023

This review explores the pivotal role of molecular profiling in the diagnosis, classification, and targeted treatment of gliomas, highlighting recent advances, challenges including the blood-brain barrier and tumor heterogeneity, and the pressing need for ongoing research to fully unlock the potential of personalized therapies for glioma patients. [Read the Full Post]

Significance of PBRM1 mutation in disease progress and drug selection in clear cell renal cell carcinoma

56 views | Nov 02 2023

This study highlights the high prevalence of PBRM1 mutation in ccRCC, its association with advanced disease stages, and identifies potential therapeutic targets and pathways for personalized treatment. [Read the Full Post]

A small molecule G6PD inhibitor reveals immune dependence on pentose phosphate pathway

125 views | Sep 16 2023

The study developed a small molecule inhibitor, G6PDi-1, that effectively targets the glucose-6-phosphate dehydrogenase (G6PD) enzyme and modulates immune responses by depleting NADPH and inhibiting inflammatory cytokine production in T cells while suppressing respiratory burst in neutrophils. [Read the Full Post]

Investigating dihydroorotate dehydrogenase inhibitor mediated mitochondrial dysfunction in hepatic in vitro models

82 views | Sep 01 2023

The study found that while DHODH inhibitors showed multifactorial toxicity and moderate indications of respiratory chain dysfunction or uncoupling in HepaRG® cells, leflunomide and brequinar specifically exhibited mitochondrial toxicity in HepG2 cells, indicating a potential role of biotransformation in mediating or masking hepatic mitochondrial liabilities. [Read the Full Post]

De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma

93 views | Sep 01 2023

The discovery of the hypersensitivity of IDH1-mutant glioma cells to DHODH inhibitors presents a promising, biomarker-guided therapeutic strategy for the treatment of aggressive glioma. [Read the Full Post]

Dichloroacetic acid and rapamycin synergistically inhibit tumor progression

207 views | Aug 15 2023

Rapamycin treatment leads to the inactivation of the pyruvate dehydrogenase complex (PDHc) through mTOR signaling inhibition, reducing cancer cells' response to rapamycin, while reactivating PDHc with dichloroacetic acid (DCA) enhances their susceptibility to rapamycin treatment. [Read the Full Post]

Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O6-methylguanine DNA methyltransferase (MGMT) expression and reactive oxygen species (ROS)-mediated DNA damage in glioblastoma

47 views | Aug 15 2023

The study found that the selective inhibitor NCT503, when combined with temozolomide (TMZ), demonstrated synergistic effects in inhibiting glioblastoma cell growth and inducing apoptosis, potentially offering a promising treatment strategy for MGMT-high glioblastoma patients. [Read the Full Post]

The expression and role of glycolysis-associated molecules in infantile hemangioma

117 views | Aug 13 2023

This study demonstrates that glycolysis-associated molecules are highly expressed in infantile hemangioma endothelial cells, and their inhibition leads to a reduction in cell proliferation, migration, and tube formation, suggesting their potential as therapeutic targets for treating infantile hemangioma. [Read the Full Post]

Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME)

60 views | Aug 01 2023

The phase 1 pilot study demonstrated that the combination of RRx-001 and nivolumab was well-tolerated, showed preliminary anti-cancer activity, and further clinical trials with this combination are warranted. [Read the Full Post]